Pelacarsen and Olpasiran: The New Generation of Lp(a)-Lowering Therapies

For decades, elevated lipoprotein(a) — Lp(a) — has been an untreatable cardiovascular risk factor. It's genetically determined, causally linked to atherosclerosis and aortic valve stenosis, and largely unmoved by diet, exercise, or most existing lipid-lowering drugs. That is now changing. Pelacarsen (Novartis/Ionis) and olpasiran (Amgen) are next-generation RNA-targeted therapies in Phase 3 cardiovascular outcomes trials, showing Lp(a) reductions of 80–95%. The first outcomes data is expected in 2026.

New to Lp(a)? Start with our complete guide to lipoprotein(a) — what it is, what counts as high, and why to measure it once.

The Problem: Lp(a) as Residual Risk

Lp(a) is a genetically determined, independent, causal risk factor for atherosclerotic cardiovascular disease, myocardial infarction, stroke, peripheral artery disease, and aortic valve stenosis.

Until now, the only available options were aggressive lowering of other risk factors (LDL-C, ApoB, blood pressure), lipoprotein apheresis for extreme cases — impractical as a long-term solution — or niacin, which lowers Lp(a) by 20–30% but has never shown an outcomes benefit. The unmet need has always been a safe, effective, convenient therapy that directly targets Lp(a) production. That's exactly what these two drugs attempt.

Pelacarsen: Antisense Oligonucleotide Therapy

Pelacarsen is an antisense oligonucleotide (ASO) that binds to apo(a) mRNA inside liver cells, blocking production of apolipoprotein(a) and reducing Lp(a) particle assembly and secretion. It's conjugated to N-acetylgalactosamine (GalNAc), which targets it specifically to hepatocytes via the asialoglycoprotein receptor — the same delivery approach used across this new generation of RNA-targeted lipid drugs.

Efficacy

Phase 2 trials demonstrated a 70–92% Lp(a) reduction across various patient populations, with individual patients at higher doses seeing reductions above 99%, and consistent efficacy regardless of baseline Lp(a) level. In a Phase 1 study of healthy Japanese subjects, a single 80 mg dose produced a 74% reduction at day 30, and four monthly 80 mg doses sustained an 84% reduction over 6+ months.

The Lp(a) HORIZON Trial

Safety Profile

Phase 2 trials showed pelacarsen to be generally well-tolerated, with no serious adverse events attributed to the drug, a low incidence of injection-site reactions (the GalNAc conjugation improves tolerability compared with earlier-generation ASOs), and no significant effects on platelets, liver enzymes, or renal function.

Olpasiran: Small Interfering RNA (siRNA) Therapy

Olpasiran is a small interfering RNA (siRNA) that silences the LPA gene directly inside hepatocytes, preventing translation of apo(a) mRNA and reducing Lp(a) production at the source. Like pelacarsen, it's GalNAc-conjugated for liver-specific delivery.

Efficacy

In the Phase 2 OCEAN(a)-DOSE trial, the highest dose (284 mg) achieved greater than 95% Lp(a) reduction, with a clear dose-dependent effect and sustained suppression over 6+ months. Notably, the extension period showed prolonged Lp(a) suppression even after treatment discontinuation, suggesting a durable gene-silencing effect rather than one requiring continuous dosing to maintain.

The OCEAN(a)-Outcomes Trial

Head-to-Head Comparison

The Competitive Landscape

Pelacarsen and olpasiran aren't alone — several other Lp(a)-lowering agents are progressing through development:

Clinical Implications

Who Will Benefit?

If the outcomes trials read out positive, these therapies will likely be indicated for:

How Will They Fit Into Practice?

The expeted treatment algorithm, if these drugs are approved, looks something like this: measure Lp(a) once in all high-risk patients, as guidelines already recommend. Optimize standard therapy first — high-intensity statin, ezetimibe if needed, and a PCSK9 inhibitor, which also lowers Lp(a) by 20–30% as a secondary effect. If Lp(a) remains elevated (≥70–80 mg/dL) with residual risk, consider adding pelacarsen or olpasiran. Ongoing monitoring would track Lp(a) reduction (target: >80% reduction or <50 mg/dL), continued ApoB/LDL-C control, and safety parameters — liver enzymes, platelets, renal function — though early data looks reassuring on all three.

Unanswered Questions

The 2026 outcomes trial readouts will need to address several open questions:

• Does Lp(a) lowering reduce cardiovascular events? This is the central question — biological plausibility is strong, but outcome data is what's actually needed.
• What magnitude of reduction is required? Is 50% enough, or does meaningful benefit require >80%?
• What baseline Lp(a) threshold justifies treatment? ≥70 mg/dL? ≥100 mg/dL? ≥180 mg/dL?
• What does long-term safety look like? Earlier-generation ASOs raised concerns about thrombocytopenia and hepatic/renal effects — GalNAc conjugation appears to mitigate these risks, but longer follow-up will confirm this.
• Can these be combined with PCSK9 inhibitors? Likely yes, given complementary mechanisms, but this needs dedicated study.

Common Questions